"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease. WHY IT'S IMPORTANT ...
Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
2d
Investor's Business Daily on MSNRoche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionRoche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
The Company has placed increased emphasis on its pharmacy gift card program to address the growing critical need for improved preventive care and affordable access to newer treatment options. By ...
The exact price depends on dosage, pharmacy, location, insurance coverage, and available savings programs. Fully understanding the various factors affecting ...
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...
Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Analysts acknowledged the long-term manufacturing deal could dull Viking’s takeout prospects but hailed it as a smart move to ensure supply.
A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over affordability ...
Wegovy and Zepbound — are cutting prices to make the medications more affordable for people without insurance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results